N-terminal pro brain natriuretic peptide in arterial hypertension - A marker for left ventricular dimensions and prognosis

European Journal of Heart Failure

Volumn 6, Issue 3, 2004, Pages 313-317

  Hildebrandt, Per ^a   Boesen, Mikael ^b   Olsen, Michael ^c   Wachtell, Kristian ^c   Groenning, Bjoern ^a  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Arterial hypertension; Cardiovascular disease; Magnetic resonance imaging; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ECG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY WEIGHTS AND MEASURES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; VENTRICULAR FUNCTION, LEFT;

EID: 1342291265     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.01.001     Document Type: Article

References (20)

1. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351:(9118):1998;1755-1762.
2. De Backer G., Ambrosioni E., Broch-Johnsen K., et al. Europeean guidelines on cardiovascular disease prevention i clinical practise. Third joint task force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 24:2003;1601-1610.
3. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 143:(5):2002;023-029.
4. Gustafsson F., Badskjær J., Hansen F.S., Paulsen A.H., Hildebrandt P. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug. 3:2003;141-146.
5. Gardner R.S., Özalp F., Murday A.J., Robb S.D., McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 24:2003;1735-1743.
6. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 86:(1):2001;21-26.
7. Nakao K., Ogawa Y., Suga S-I., Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens. 10:1992;907-912.
8. Bellenger N.G., Burgess M.I., Ray S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 21:2000;1387-1396.
9. Alfakih K., Plein S., Thiele H., Jones T., Ridgway J.P., Sivananthan M.U. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging. 17:2003;323-329.
10. Luchner A., Burnett J.C., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 18:2000;1121-1128.
11. Wachtell K, Olsen MH, Hall C. Is NT-pro brain natriuretic peptide related to systolic and diastolic left ventricular function at baseline and during antihypertensive treatment. (abstract, ACC 2003), Circ 2003.
12. Murakami Y., Shimada T., Inoue S., et al. New insights into mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol. 18:(12):2002;1294-1300.
13. Mussalo H., Vanninen E., Ikäheimo R., Hartikainen J. NT-proANP and BNP in renovascular and in severe and mild essentila hypertension. Kidney Blood Press R. 26:2003;34-41.
14. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. J Am Med Assoc. 288:2002;1252-1259.
15. Freitag M.H., Larson M.G., Levy D., et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham heart study. Hypertension. 41:2003;978-983.
16. Suzuki M., Hamada M., Yamamoto K., Kazatani Y., Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res. 25:(5):2002;669-676.
17. Olsen MH, Wachtell K, Tuxen C, et al. N-terminal proBrain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. A LIFE study. J Hypertension. 2003. In press.
18. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide a norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (Val-Heft). Circulation. 106:(19):2002;2454-2458.
19. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Neurohormonal prediction of hemodynamic benefit from ß-blockade with metoprolol in chronic heart failure. Eur J Heart Fail. 4-5:2002;635-646.
20. Groenning BA, Hildebrandt PR, Riegger GA, et al. Brain natriuretic peptide and N-terminal pro brain natriuretic peptide for treatment monitoring in patients with left ventricular systolic heart failure-a substudy of the CARMEN trial (abstract, ESC 2003). Eur Heart J 2003.